RxDoctor Payments Data

Chirag Patel, MD

Internal Medicine · East Point, GANPI 1225008758

Payments from drug & device makers

$1,578in general payments, 2019–2025

Across 26 payments — averaging $60.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$441
  • Voom Medical Devices, Inc.$373
  • Boston Scientific$319
  • Bayer$124
  • Merck$100
  • Johnson & Johnson$54
  • plus $168 from 6 others

What the payments were for

  • Travel & lodging$37324%
  • Food & beverage$1,20676%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca5$441
Voom Medical Devices, Inc.1$373
Boston Scientific6$319
Bayer1$124
Merck1$100
Johnson & Johnson2$54
Amgen2$42
GSK2$38
Novartis2$31
Astellas Pharma US Inc2$25
Dexcom, Inc.1$17
Boehringer Ingelheim1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,578 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$48,359
Medicare patients
83
Services billed
596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$51,410
JanuviaSitagliptin Phosphate45$37,876
FarxigaDapagliflozin Propanediol21$19,892
XareltoRivaroxaban15$16,558
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,566
MyrbetriqMirabegron13$8,292
SymbicortBudesonide/Formoterol Fumarate11$6,252
Spiriva HandihalerTiotropium Bromide12$5,905
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp23$5,155
Atorvastatin Calcium553$3,162
Levemir FlexpenInsulin Detemir13$2,509
Albuterol Sulfate HfaAlbuterol Sulfate62$2,269
Nifedipine ErNifedipine86$2,128
Gabapentin110$1,635
Amlodipine Besylate503$1,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$100$37,87645 claims
AstraZenecaFarxiga, Symbicort$441$26,14432 claims
Johnson & JohnsonXarelto$54$16,55815 claims
GSKTrelegy Ellipta$38$9,56613 claims
Astellas Pharma US IncMyrbetriq$25$8,29213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in East Point

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →